The Liver Disease 30% of Us Have and Never Feel | Prof Aleksander Krag

Steatotic liver disease, characterized by excess fat accumulation in the liver, affects approximately 30% of the global population and frequently progresses asymptomatically toward fibrosis and cirrhosis. Prof. Aleksander Krag emphasizes that while early detection is critical, the condition remains largely reversible if clinicians and patients address core drivers like metabolic dysfunction and alcohol consumption. Shifting from stigmatizing labels to the term "steatotic liver disease" reflects a more precise understanding of the condition's metabolic origins. Diagnostic strategies now prioritize the FIB-4 index and abdominal circumference as accessible screening tools to identify high-risk individuals before irreversible scarring occurs. Recent breakthroughs, including GLP-1 agonists and resmetarom, provide promising pharmacological interventions that, when combined with lifestyle modifications, offer significant potential for preventing or reversing advanced liver damage.